Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented with hypoglycaemic coma. These features have not previously been reported as side effects of glibenclamide therapy, but intrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent. The mechanism of this cholestasis is not clear at present.
Introduction
Glibenclamide, a potent oral hypoglycaemic drug (Aumuller et al., 1966) , has been considered to have fewer adverse effects than chlorpropamide which is an equivalent sulphonylurea agent. A diabetic patient presenting with hypoglycaemia is described who had reversible intrahepatic cholestasis and cutaneous bullae which appeared to have been induced by a 10 mg dose of glibenclamide.
Case history
A 61-year-old man with a 17-month history of maturity-onset diabetes mellitus, retinopathy and mild proteinuria was admitted unconscious with a blood glucose of less than 1-5 mmol/l. He He rapidly recovered consciousness with intravenous dextrose and 1 mg glucagon intramuscularly. Bilirubin, aspartate and alanine amino-transaminases returned to normal levels by the fourth day and alkaline phosphatase was normal after the thirtyseventh day. Both bullae gradually dried up over one month. Digoxin, frusemide and Slow-K were continued without any adverse effect. His diabetes was controlled by diet alone and he remains well on follow-up 3 months later.
Discussion
Glibenclamide is a potent and long-acting sulphonylurea drug which is relatively free of adverse effects. By contrast, its predecessor chlorpropamide has a number of adverse effects including intrahepatic cholestasis in 0 5 % of patients (Reichel et al., 1960 Zucker and Simon, 1968. 12. O'Sullivan and Cashman, 1970 6. Bell, 1964 13. Burns, 1969 7. Boyle et al., 1972 14. Clarke et al., 1974 15. Shaw, Bloom, and Bulpitt, 1977 elevation of aspartate and alanine aminotransaminases which are reversible without alteration to dosage (Burns, 1969; O'Sullivan and Cashman, 1970) . It is also known to cause minor gastrointestinal disturbances (Burns, 1969), hypoglycaemia (Sillence and Court, 1975) , which can be fatal especially in the elderly (Gottesbiuren et al., 1970) and nocturia (Shaw, Bloom and Bulpitt, 1977) . In one patient glibenclamide therapy was associated with a severe generalized hypersensitivity reaction resulting in fatal toxic erythema, cholestasis, eosinophilia and renal failure (Clarke et al., 1974) . Post-mortem revealed a necrotizing angiitis with associated granulomatous changes in the spleen and kidneys. The combination of reversible intrahepatic cholestasis and cutaneous bullae due to glibenclamide has not previously been recorded. In this patient the probable diagnosis of drug-induced intrahepatic cholestasis was determined by exclusion of extrahepatic biliary obstruction, viral hepatitis and primary liver disease. The cholestasis cleared within 5 weeks of glibenclamide withdrawal, whilst other drug therapy was continued. It was felt that rechallenge with glibenclamide might carry a risk and was therefore unethical, especially as the patient did not require an oral hypoglycaemic drug to control his diabetes mellitus.
The two cutaneous bullae resembled those occasionally produced by barbiturate poisoning or seen in porphyria cutanea tarda. However, both these diagnoses were excluded and as no further bullae have appeared they too were probably an adverse reaction to glibenclamide therapy.
The mechanism of glibenclamide-induced intrahepatic cholestasis and cutaneous bullae is uncertain, although a hypersensitivity reaction in association tase reports with toxic erythema and cholestasis was reported in a fatal case (Clarke et al., 1974) . It has been suggested that a hypersensitivity reaction would account for chlorpropamide-induced intrahepatic cholestasis (Friedman, 1962 
